Is Cancer Increasing in the U.S.? Why Death Rates Are Falling While Diagnoses and Costs Remain High

The United States is making measurable progress against cancer, but that progress does not mean fewer Americans will receive a diagnosis or that treatment has become easier to afford. The American Cancer Society’s Cancer Statistics, 2026 report projects 2,114,850 new cancer cases and 626,140 cancer deaths in 2026: nearly 5,800 diagnoses and 1,715 deaths per day. Those are forecasts, not counts of events already recorded in 2026.

At the same time, the nation’s age-adjusted cancer death rate has fallen substantially. The American Association for Cancer Research’s 2026 progress report documents a 35% decline from the 1991 peak through 2024. People are surviving cancers that were once far more frequently fatal.

Both findings can be true. The total number of diagnoses is affected by the size and age of the population. The risk of developing cancer changes differently across cancer types, sexes and age groups. More effective prevention, screening and treatment can reduce deaths without eliminating new cases. Meanwhile, more people living with or beyond cancer need follow-up care, and some face substantial out-of-pocket expenses, lost income and administrative barriers.

There is a genuine warning within the encouraging national picture: several cancers, particularly colorectal cancer, are becoming more common among some younger adults. But the evidence does not show that every cancer is surging in everyone under 50.

To understand where the country stands, we need to keep four questions separate: How many cancers are diagnosed? How is the risk of cancer changing? How many people die from it? And what happens to patients between an abnormal finding, diagnosis, treatment and recovery?

Is cancer increasing in the United States in 2026?

The answer depends on whether we mean the number of diagnoses or the rate at which cancer occurs in a population adjusted for age.

The latest figures are not all measurements from 2026

Cancer registries need time to collect, verify and consolidate records. The American Cancer Society’s 2026 projections draw on incidence data available through 2022 and death records through 2023. A forecast for this year should therefore not be mistaken for evidence that cancer incidence suddenly increased during this year.

Sources: ACS cancer statistics; the joint 2026 Annual Report to the Nation; and the AACR Cancer Progress Report 2026. The 2026 ACS paper reports 70% five-year relative survival for diagnoses during 2015-2021, while AACR cites 71% for the later 2016-2022 cohort. They are different observation windows, not conflicting measurements of the same cohort.

Why diagnosis counts and cancer risk can move in different directions

Imagine a population in which the cancer incidence rate at each age remains unchanged. If that population grows, its total cancer diagnoses can still rise. If a larger share of residents reaches older ages, diagnoses can rise further because cancer risk generally increases with age. Neither development requires a sudden increase in the risk faced by a person of any particular age.

That is why epidemiologists use age-adjusted incidence rates, usually expressed as new cancers per 100,000 people after standardizing populations to the same age distribution. These rates permit comparisons that raw counts do not.

The distinction also explains the different findings for men and women. According to the 2026 Annual Report to the Nation, the overall age-adjusted incidence rate stabilized among men after 2013 but increased slowly among women through 2022. Looking at all Americans as a single group would hide those differences, and looking only at projected annual case counts would hide them even more.

There are additional limits to the headline estimate. As described in the ACS report’s methodology, the standard national projection excludes certain common cancers, particularly basal and squamous cell skin cancers that are not routinely counted in population cancer registries. It should not be described as every malignancy diagnosed nationwide.

Why are cancer death rates falling while diagnoses remain high?

Cancer mortality has improved because multiple advances have accumulated over decades. There is no single drug, screening test or public-health campaign that explains the whole reduction.

The most important broad factors include falling tobacco use, earlier detection of some cancers and treatments that keep more people alive after diagnosis. The 2026 AACR progress report identifies the long decline in lung cancer deaths, driven substantially by lower smoking rates and reinforced by advances in diagnosis and treatment, as a central contributor to the national mortality improvement.

The joint 2026 national surveillance report shows that lung and bronchus cancer death rates fell by an average of 4.7% annually among men and 3.0% among women during 2019-2023. These changes matter greatly because lung cancer remains the country’s leading cause of cancer death.

Other gains come from different mechanisms. Colorectal screening can identify and remove precancerous polyps, potentially preventing a cancer rather than merely detecting it earlier. Mammography can identify some breast cancers before symptoms develop. Improvements in surgery, radiotherapy, systemic drug treatment, immunotherapy and molecularly targeted treatment have changed outcomes for selected cancers and patient groups.

But falling mortality does not mean all cancers are improving at the same pace. Some malignancies remain difficult to detect early or treat successfully, and outcomes vary considerably by stage, age, tumor biology and access to care. The national trend is real; so are its exceptions.

Why five-year survival is not the same as curing cancer

The overall five-year relative survival figure is an important measure of progress, but it is commonly misunderstood. It compares survival among people diagnosed with cancer to expected survival among otherwise similar people in the general population. It is not an estimate that every newly diagnosed patient has a 71% chance of recovery.

Survival statistics are also affected by lead-time bias: detecting a cancer earlier can lengthen the measured time from diagnosis to death even when the date of death does not change. Overdiagnosis occurs when screening detects cancers that would never have caused symptoms or death during a person’s lifetime, which can also increase recorded survival without necessarily saving lives.

For these reasons, improved survival figures should be evaluated alongside cancer-specific mortality, stage at diagnosis, quality of life and randomized screening outcomes. It matters whether a treatment extends life, whether a screening program prevents advanced disease, and whether its benefits exceed the harms of unnecessary testing and treatment. The National Cancer Institute’s screening evidence review explains these measurement problems.

Which cancers are increasing and which are declining?

A single national cancer trend obscures important differences. The table below summarizes observed age-adjusted incidence trends, rather than projected 2026 diagnosis counts.

Source: 2026 Annual Report to the Nation, age-adjusted cancer incidence by sex and type. Unless otherwise stated, the trend window is 2018-2022. “Broadly stable” means no meaningful measured overall change in that surveillance period; it is not a claim that every age group was stable.

There is another distinction worth making: incidence and mortality can move in opposite directions for the same cancer. Diagnoses can rise as a result of increased detection or underlying risk while deaths fall because treatment has improved. Conversely, a cancer may become less common overall while death rates rise in a particular younger group.

The clearest example of the latter is colorectal cancer.

Are more people under 50 developing cancer?

Certain early-onset cancers are becoming more common. That is established. An across-the-board explosion in cancer among everyone under 50 is not.

A major National Cancer Institute-led study published in Cancer Discovery in 2025 examined trends in 33 cancer types during 2010-2019. Incidence increased in at least one younger age group for 14 cancer types, but decreased for 19. Nine of the 14 increasing types also rose in at least one older age group.

The study examined younger ages in separate bands, including ages 15-29, 30-39 and 40-49. Its findings therefore cannot be reduced to a claim that the same increase occurred uniformly among all people under 50. In the period studied, the overall age-adjusted cancer incidence rate across cancer types did not increase in the combined younger and older age-group analyses.

A more recent NCI analysis published in the Journal of the National Cancer Institute in July 2026 used surveillance data through 2023 for 22 common cancer types in people under 50. It reported continued increases in selected cancers, including colorectal and ovarian cancer, while finding that trends changed differently for other cancers. Because the two studies examined different cancer sets and time windows, their counts should not be merged.

The 2026 Annual Report to the Nation likewise found that the overall cancer incidence rate among adolescents and young adults ages 15-39 was stable during 2018-2022, even as breast, testicular and colorectal incidence increased within that group. A stable all-cancer average does not cancel out individual increases; it describes the net result after considering the different cancer types.

The strongest warning is colorectal cancer

The American Cancer Society’s Colorectal Cancer Statistics, 2026 identifies a striking age divide:

Sources: ACS colorectal cancer statistics and the 2026 national surveillance report. The age ranges and observation windows differ intentionally; these are not additive groups.

Mortality is also moving in the wrong direction for some younger adults: the ACS colorectal analysis reports that colorectal cancer death rates increased about 1% annually among adults under 50 since 2004, despite declines among older adults. Colorectal cancer is now the leading cause of cancer death in Americans younger than 50 when men and women are considered together.

The rise is not simply a consequence of expanded screening. A lower recommended screening age has increased detection, particularly of localized disease among those 45-49, but the longer-term incidence trend predates that change. The ACS analysis also finds increased incidence concentrated in the distal colon and rectum. It reports that roughly three in four colorectal cancers diagnosed before age 50 are already regional- or distant-stage at diagnosis.

It would nevertheless be misleading to suggest that younger adults account for most U.S. cancer diagnoses. Cancer risk remains much higher at older ages, as explained in the NCI’s age-and-cancer-risk guidance. The concern is that some younger-age rates are increasing from a lower baseline, often during years when symptoms may not immediately raise suspicion of cancer.

What might be driving early-onset cancers?

Scientists are investigating changes in diet, obesity and metabolic disease, alcohol exposure, microbiome composition, infection-related risks, environmental exposures and factors acting earlier in life. Inherited susceptibility also matters for some patients. But these possibilities are not interchangeable explanations, and the evidence for one cancer cannot automatically be applied to another.

We know from decades of research that smoking increases the risk of several cancers, alcohol contributes to cancer risk, and excess body weight is associated with multiple malignancies. A 2024 American Cancer Society analysis estimated that approximately 40% of new cancers and 44% of cancer deaths among U.S. adults age 30 and older in 2019 were attributable to the potentially modifiable risk factors evaluated in that model. This is a population estimate for a particular year, not a statement that an individual patient could necessarily have prevented their cancer.

More importantly, knowing that a risk factor causes cancer is not the same as demonstrating that it caused a recent increase in cancer incidence. If rates of a particular cancer rise in successive birth cohorts, researchers still need evidence linking the shift to specific exposures, biological mechanisms, detection practices or combinations of causes. The NCI’s Early-Onset Cancer Initiative is investigating these questions.

There is currently no credible single explanation for every early-onset cancer trend. Treating one proposed culprit as the answer would be more dramatic than the evidence permits.

Should people under 50 get screened for cancer earlier?

The response to rising early-onset incidence should be evidence-based screening for the right populations, evaluation of symptoms at any age, and individualized care for people at higher risk. It should not be indiscriminate testing for every possible cancer.

What established U.S. screening guidance recommends

The U.S. Preventive Services Task Force (USPSTF) colorectal screening recommendation calls for routine screening in average-risk, asymptomatic adults starting at 45, continuing through 75. Screening decisions from ages 76-85 are individualized. Options include stool-based testing and colonoscopy, with different testing intervals and follow-up requirements. A positive stool-based screening test generally requires diagnostic colonoscopy rather than simply repeating the screening test.

For breast cancer, the USPSTF recommendation is mammography every two years from ages 40 through 74 for people to whom its average-risk guidance applies. That recommendation does not substitute for high-risk screening plans in people with certain inherited variants, prior chest radiation or other high-risk histories.

Lung cancer screening with annual low-dose CT is recommended for adults ages 50-80 with at least a 20 pack-year smoking history who currently smoke or quit within the previous 15 years. A pack-year means the equivalent of smoking one pack per day for one year. Cervical cancer screening also remains important, with appropriate testing depending on age and clinical circumstances.

People with strong family histories, known hereditary cancer syndromes, previous high-risk findings or certain medical conditions may need different testing or earlier surveillance. These decisions require an individualized risk assessment rather than a blanket change to population-wide screening ages.

Symptoms are not a screening-age question

Screening is intended for people without symptoms. A 30-year-old with persistent rectal bleeding is not asking the same medical question as an asymptomatic 30-year-old asking for routine screening.

The CDC’s colorectal cancer symptom guidance, updated in June 2026, identifies blood in stool, persistent bowel-habit changes, ongoing abdominal pain, unexplained weight loss and iron-deficiency anemia among signs that warrant medical evaluation. Many of these problems have noncancerous causes, but age alone should not be used to dismiss them. The NCI’s broader cancer symptom guidance similarly advises medical assessment for persistent or unexplained changes.

The practical rule is straightforward: follow screening recommendations when asymptomatic, and seek diagnostic evaluation when concerning symptoms develop, regardless of whether the routine screening age has arrived.

What the 2026 multicancer blood-test trial actually found

Blood tests intended to detect several cancers at once have generated considerable attention. The central question is not whether a test can identify cancer-related signals. It is whether offering the test to people without symptoms reduces advanced disease or cancer deaths enough to outweigh false positives, additional procedures and overdiagnosis.

The NHS-Galleri randomized trial published in the New England Journal of Medicine on September 22, 2026 enrolled 142,250 adults ages 50-77 in England. Participants received usual care, with one group also having blood samples analyzed using a multicancer early-detection test over three screening rounds.

The trial did not meet its primary endpoint: incidence of stage III or IV cancer across 12 prespecified cancers was not significantly lower with additional blood testing (incidence-rate ratio 1.03; 95% confidence interval, 0.92-1.14; P = 0.63). A secondary analysis suggested fewer stage IV cancers (incidence-rate ratio 0.86; 95% confidence interval, 0.74-1.00), but the investigators called for further follow-up. The published findings did not establish that the test reduces cancer mortality. GRAIL, the test developer, funded the trial.

That result does not show that every future multicancer test will fail, or that blood-based screening for a specific cancer cannot be useful. It does show why an encouraging detection claim is insufficient evidence for routine population screening. These tests should not be treated as substitutes for screening that has demonstrated benefit.

How much does cancer care actually cost in the United States?

Cancer care costs hundreds of billions of dollars nationally under some published estimates. But the amount depends on the year measured, whether the figure is observed or projected, which services are counted and whose financial burden is being described.

The frequently repeated claim that U.S. cancer care is expected to cost more than $245 billion by 2030 has a traceable origin. It is not a newly calculated 2026 estimate.

Where the $245.6 billion figure came from

In a 2020 study published in Cancer Epidemiology, Biomarkers & Prevention, researchers led by Angela Mariotto modeled national cancer-attributable medical spending among survivors. They used older SEER-Medicare data, medical claims and estimated care costs at different stages of the cancer journey, then applied those estimates to projected survivor populations.

The central scenario projected a rise from approximately $182.6 billion in 2015 to $245.6 billion in 2030, expressed in constant 2019 U.S. dollars. The increase in that scenario resulted from projected population growth and aging, with incidence, survival and cost patterns held constant. It was not a prediction incorporating all future drug price increases, technology changes or shifts in cancer risk.

That study remains an important reference for the scale of national spending. But reporting its 2030 figure without the publication date, price year and model assumptions makes the estimate sound more current and comprehensive than it is.

Why another 2026 study cites $236.2 billion for 2020

A 2026 review in JNCI Monographs comparing cancer-care costs across 39 countries reported approximately $236.22 billion in direct U.S. cancer costs for 2020, converted to 2022 U.S. dollars. The study drew on earlier country-specific research and expenditure estimates, rather than a fresh audit of every U.S. cancer-care bill for that year. Its U.S. estimate used a care-phase modeling approach related to the earlier national literature.

It also reported $129,494 per diagnosis for the United States. That is a cross-country accounting ratio: modeled annual national cancer expenditure divided by annual new diagnoses. It does not mean the average newly diagnosed American receives a $129,494 treatment bill, or that this is an average lifetime cost per patient. National annual spending also includes treatment and follow-up for people diagnosed in earlier years.

Cancer cost figures: what they really measure

Sources: Mariotto and colleagues, 2020; 39-country spending review, 2026; and the NCI’s 2019 patient economic-burden estimates. These estimates use different definitions, years and modeling choices; they should not be presented as a single time series or added together.

The financial burden experienced by patients is different

The NCI’s analysis of patient economic burden estimated $21.09 billion in 2019, including $16.22 billion in out-of-pocket expenses and $4.87 billion in the economic value of time patients spent traveling to, waiting for and receiving care. This is not a complete estimate of every lost paycheck, caregiver hour or long-term household consequence.

A patient’s actual burden depends on insurance, treatment location, deductible and coinsurance rules, drug benefits, employment, travel and the length of treatment. Costs also vary considerably by cancer site, stage and phase of care. Someone receiving short-course treatment for an early-stage tumor does not have the same medical or financial trajectory as someone needing years of treatment for advanced disease.

The NCI describes the resulting distress as financial toxicity: the financial harm and stress associated with medical care, which can affect household stability and care decisions. Insurance coverage can reduce exposure without eliminating deductibles, travel expenses, lost work time or the need to challenge bills and authorizations.

The national cost story, then, is not simply that expensive treatments exist. It is that patients, insurers and public programs must finance care over longer and often more complex periods, while the households affected do not have equal financial reserves or access to support.

What is a cancer patient navigator, and when is one useful?

A cancer patient navigator helps people overcome practical barriers to diagnosis, treatment and follow-up. Depending on the program, this may include scheduling, locating specialists, understanding the care plan, arranging transportation, finding financial assistance, coordinating referrals and connecting patients with community resources.

The term covers different jobs. The American Cancer Society’s patient-navigation guide distinguishes nonclinical navigators, oncology nurse navigators, financial navigators and other specialized roles.

• A nonclinical patient navigator may help with appointments, transportation, records, language services and referrals to support resources. They do not replace the oncology team in making medical decisions.
• An oncology nurse navigator can combine coordination with clinically informed education and assessment within professional scope.
• A social worker may address counseling, family and caregiving needs, community support and financial or social barriers.
• A financial navigator or counselor can help patients understand coverage, estimate bills, review assistance programs and identify insurance problems.

The highest-value intervention depends on the obstacle. Someone who has not completed diagnostic follow-up after an abnormal screening test may need rapid scheduling and transportation. Someone newly diagnosed may need specialist coordination and assistance understanding treatment choices. Someone on chemotherapy may need clear access to symptom-management instructions, while another patient needs urgent financial counseling.

Navigation is not a guarantee that a specialist has an earlier appointment, that a bill will be covered or that treatment outcomes will improve. Its purpose is to reduce avoidable barriers within the care system.

Does patient navigation improve outcomes or save money?

It can improve some measurable outcomes, particularly participation in screening and follow-up. Other benefits are less certain, and the evidence cannot be transferred indiscriminately between different kinds of support.

A 2025 JAMA Internal Medicine meta-analysis examined 42 randomized trials involving 39,111 participants. Compared with usual care or active controls, navigation was associated with estimated absolute increases of 13.8 percentage points for breast cancer screening and 15.6 percentage points for cervical cancer screening. Follow-up after abnormal breast screening results also improved. The trial results varied substantially, and follow-up evidence was based on fewer studies than initial screening evidence. The analysis did not establish a population-level reduction in cancer mortality.

By contrast, a 2025 randomized CAFÉ trial of financial navigation after a cancer diagnosis assigned 371 patients at two integrated health systems to brief or extended navigation or enhanced usual care. Among 283 participants completing 12-month follow-up, the trial found no statistically significant differences in financial hardship or cancer-related quality of life across the groups. Everyone received at least a financial-resource list. The result does not show that financial assistance is pointless; it shows that these particular navigation strategies did not significantly improve the measured endpoints in that setting.

Another study offers a related, but importantly different, lesson. The PRO-TECT cluster-randomized trial published in Nature Medicine in 2025 tested weekly electronic symptom reporting and clinician alerts among 1,191 patients with metastatic cancer at 52 oncology practices. It found fewer emergency-department visits and better measures of symptoms, functioning and quality of life, but no overall survival advantage. Electronic symptom monitoring is a care-coordination tool, not the same intervention as assigning a navigator.

Sources: JAMA navigation meta-analysis; CAFÉ randomized trial; PRO-TECT randomized trial; and the CMS-funded independent evaluation. These interventions, populations and endpoints are different; the table is an evidence comparison, not a ranking.

What the Medicare oncology-model evaluation actually found

The federal Enhancing Oncology Model encourages participating oncology practices to deliver coordinated care through multiple activities, including patient navigation, care planning, electronic symptom reporting and screening for health-related social needs. It is a broader practice-payment and care-delivery model, not a clinical trial of one navigator intervention.

Its first independent evaluation, published in August 2025, assessed the first six-month performance period. Evaluators estimated $13.1 million in gross reductions in episode spending. Once enhanced-service and performance payments to practices were included, the estimated net impact was a $13.2 million loss to Medicare, with a broad uncertainty range extending from a $35.1 million loss to $8.5 million in savings.

Those results are too early and uncertain to establish whether the model will ultimately save money. They also cannot isolate the contribution of navigation from drug prescribing, symptom management and other redesign activities.

A useful evaluation must ask which outcome matters: Did patients complete screening? Receive diagnostic follow-up? Avoid preventable delays or visits? Experience less financial hardship? Live longer? And what was the cost of delivering the intervention? A positive answer to one is not automatically an answer to the others.

How can patients and families get help navigating cancer care?

The first practical step is to ask the oncology practice or hospital what navigation services exist and who is responsible for coordinating them. The patient should not have to guess whether to call a scheduler, nurse, social worker, insurer or financial office for every obstacle, but the services available differ by organization and insurance plan.

The NCI’s list of questions to ask before cancer treatment provides a useful starting point. The following sequence adapts that guidance to the clinical and financial barriers described above.

1. Establish the diagnosis and the immediate plan

Ask for access to the pathology report, imaging reports and other relevant records. Find out the cancer type, stage if known, whether additional molecular or biomarker testing is needed, and which decisions are time-sensitive. Ask what treatment is intended to accomplish: cure, long-term control, reduction in recurrence risk or relief of symptoms.

Also identify the person to call between visits and the number for urgent after-hours advice. A second opinion may be appropriate when treatment options differ or major decisions are being made, but the timing should be discussed with the treating team when care is urgent.

2. Request the specific support you need

Ask: "Does this practice have an oncology nurse navigator, patient navigator, social worker or financial navigator, and how can I contact that person?"

If there is no formal navigation program, ask who handles specialist referrals, treatment authorizations and financial counseling. Your health insurer may have a separate case-management or navigation service. Community organizations may help with transportation, lodging, translation or caregiving needs, although availability and eligibility vary.

For patients who have not yet received a diagnosis, navigation can also help ensure that an abnormal screening result is followed by the correct diagnostic appointment. Completing that handoff is one of the areas in which randomized evidence is particularly relevant.

3. Understand what treatment may cost before bills accumulate

When feasible, obtain written estimates and clarify whether the treating physicians, facility, laboratory, imaging center and specialty pharmacy are in network. Ask about the deductible, coinsurance, out-of-pocket maximum, prior authorization and anticipated prescription expenses. Request financial counseling early rather than waiting until bills become unmanageable.

Keep a dated record of whom you spoke with, what was authorized, and any claims or appeals. Ask whether the care team can document medical necessity when an authorization is denied. Financial counselors may know about assistance programs, but the availability of aid should never be assumed.

4. Check whether Medicare will cover navigation

Medicare Part B covers principal illness navigation services for eligible beneficiaries. The condition must be serious, generally expected to last at least three months, and associated with specified risks such as hospitalization, significant decline or death. An initial provider visit is required, and covered navigation can continue monthly under program rules.

After the Part B deductible, beneficiaries generally owe 20% of the Medicare-approved amount, subject to other coverage they may have. This is not automatically free, is not offered by every practice and is distinct from the Enhancing Oncology Model’s payments to oncology practices. Confirm eligibility, availability and personal costs with the provider and insurer.

5. Address younger-adult needs before treatment starts

People diagnosed during their working and family-building years may have concerns not addressed by standard oncology scheduling: fertility, raising children, supporting aging relatives, job protection, insurance continuity, relationships and long-term treatment effects.

A 2026 review in the American Society of Clinical Oncology Educational Book emphasizes these issues in early-onset cancer care. If a proposed treatment could affect fertility, discuss preservation options before treatment begins, when clinically feasible. Not every treatment threatens fertility, and available options depend on the diagnosis, regimen, urgency and individual circumstances.

6. Make symptom monitoring and survivorship part of the plan

Before treatment starts, ask which side effects should prompt a same-day call, which require emergency care, and whom to contact outside office hours. A navigator can help make sure instructions and contact details are clear, but urgent medical symptoms need the appropriate clinical response, not merely administrative follow-up.

When treatment ends or changes, request a plan covering follow-up tests, medication, possible late effects, rehabilitation and the transition back to primary care or other specialists. For many patients, the work of living with or beyond cancer continues long after the first treatment course.

A short checklist to bring to an appointment

• [ ] What exactly is the diagnosis, and what additional information is still needed?
• [ ] What are the treatment goals, alternatives, risks and time-sensitive decisions?
• [ ] Who coordinates referrals, authorizations, records and appointments?
• [ ] Is an oncology or financial navigator available, and what would it cost me?
• [ ] What expenses should I anticipate beyond treatment itself?
• [ ] Who do I call for symptoms during the day, after hours or in an emergency?
• [ ] Do I need to discuss fertility, employment, caregiving or other practical concerns before treatment?
• [ ] What will monitoring, follow-up and survivorship care involve?

What should the United States measure next?

The next phase of cancer progress requires several different kinds of evidence, not one headline number.

For early-onset cancer, researchers need to identify which exposures and mechanisms explain rising rates in particular cancer types and birth cohorts, separating true changes in risk from changes in screening and diagnosis. For screening, new technologies must demonstrate meaningful clinical outcomes, not merely their ability to detect more abnormalities. For treatment, longer survival must be considered alongside side effects, quality of life, affordability and unequal access.

For care navigation, the research challenge is to distinguish programs that increase screening or improve follow-up from those that reduce financial hardship, avoidable hospital use or mortality. Different programs may deliver different benefits. Independent trials and rigorous evaluations are needed before a particular strategy is called cost-saving or lifesaving.

The central finding from the 2026 evidence is clear: the United States has substantially reduced the population-adjusted risk of dying from cancer, while the burden of new diagnoses, some rising younger-age cancers and the economic cost of care remain serious problems. Recognizing that progress and those unresolved problems together is more informative than claiming either that cancer is being defeated or that every trend is getting worse.

References and Further Reading

National cancer incidence, mortality and survival

• Siegel and colleagues, Cancer Statistics, 2026 — CA: A Cancer Journal for Clinicians, January 2026. Primary source for 2,114,850 projected diagnoses, 626,140 projected deaths, historical mortality trends and five-year survival. Incidence data extend through 2022; mortality data through 2023.
• Annual Report to the Nation on the Status of Cancer, 2026 — NCI, CDC, ACS and partner surveillance organizations. Source for observed sex-, age- and cancer-specific incidence and mortality trends.
• AACR Cancer Progress Report 2026, Executive Summary — American Association for Cancer Research. Reports the 35% cancer mortality decline through 2024 and 71% five-year relative survival for the 2016-2022 diagnosis cohort.
• SEER Cancer Stat Facts: Cancer of Any Site — NCI registry context for incidence, mortality and population-based survival definitions.

Early-onset cancer and cancer prevention

• Shiels and colleagues, trends in early-onset and older-onset cancer, 2010-2019 — Cancer Discovery, 2025. Original analysis of 33 cancer types and the 14 types with increased incidence in at least one younger age group.
• Hong and colleagues, recent trends in early-onset cancer incidence — Journal of the National Cancer Institute, July 2026. Analysis of 22 common cancers in people under 50 incorporating incidence data through 2023.
• Siegel and colleagues, Colorectal Cancer Statistics, 2026 — CA: A Cancer Journal for Clinicians, March 2026. Primary source for diverging colorectal cancer incidence and mortality trends by age, along with screening uptake and stage at diagnosis.
• Islami and colleagues, potentially modifiable cancer risk factors in the United States — CA: A Cancer Journal for Clinicians, 2024. Population-attributable estimates for selected exposures in adults age 30 and older in 2019.
• Early-Onset Cancer Initiative — National Cancer Institute. Explains the scope of ongoing research into younger-age cancer trends and possible causes.

Screening recommendations and clinical evidence

• USPSTF colorectal cancer screening recommendation — Screening from age 45 for average-risk adults, with age-specific grades and test options; guidance concerns people without symptoms.
• USPSTF breast cancer screening recommendation — Biennial mammography ages 40-74 for the applicable population; includes important high-risk exclusions.
• USPSTF lung cancer screening recommendation — Criteria for low-dose CT screening based on age and smoking history.
• Sasieni and colleagues, randomized NHS-Galleri multicancer screening trial — New England Journal of Medicine, September 2026. Primary randomized evidence showing no statistically significant reduction in the trial’s combined stage III-IV cancer endpoint after three screening rounds; funded by GRAIL.
• CDC, Symptoms of Colorectal Cancer — Updated June 2026. Distinguishes symptom evaluation from routine screening.
• NCI, Symptoms of Cancer — Explains why persistent unexplained symptoms merit medical evaluation even though many have noncancerous causes.

National medical spending and patient financial burden

• Mariotto and colleagues, medical care costs associated with cancer survivorship — Cancer Epidemiology, Biomarkers & Prevention, 2020. Original model producing the $245.6 billion projection for 2030 in constant 2019 dollars.
• Ngo and colleagues, direct cancer-care costs in 39 countries — JNCI Monographs, 2026. International comparison reporting modeled U.S. 2020 direct costs in 2022 dollars; its per-diagnosis value is a national expenditure ratio, not an individual bill.
• NCI, Annual Report to the Nation Part 2: Patient Economic Burden — Estimates 2019 patient out-of-pocket and time costs separately from broader national medical spending.
• NCI, Financial Toxicity and Cancer Treatment — Reviews financial distress and the ways treatment expenses can affect patients and families.

Patient navigation, care coordination and Medicare coverage

• Nelson and colleagues, patient navigation for breast and cervical cancer screening — JAMA Internal Medicine, 2025. Meta-analysis of 42 randomized trials assessing screening uptake and follow-up, not cancer mortality.
• Henrikson and colleagues, the CAFÉ financial-navigation trial — JCO Oncology Practice, 2025. Randomized trial finding no statistically significant improvement in financial hardship or quality of life after the tested interventions.
• Basch and colleagues, final PRO-TECT randomized trial results — Nature Medicine, 2025. Evaluates electronic symptom monitoring, showing improvements in selected outcomes but not overall survival.
• Enhancing Oncology Model: First Annual Evaluation Report — Lewin Group and Westat for CMS, August 2025. Original early-period gross and net Medicare spending estimates and uncertainty ranges.
• CMS, Enhancing Oncology Model — Explains participating-practice care redesign activities and the model’s structure.
• Medicare, Principal Illness Navigation Services — Current eligibility and Part B cost-sharing information; distinct from the Enhancing Oncology Model.
• American Cancer Society, Patient Navigation in Cancer Care — Explains what different navigators can and cannot do, and common barriers they address.
• NCI, Questions to Ask Your Doctor About Treatment — Patient-oriented questions about treatment goals, benefits, side effects, clinical trials and second opinions.
• Bergerot and colleagues, care challenges in early-onset cancer — ASCO Educational Book, 2026. Specialist review of fertility, psychosocial effects, employment, caregiving and survivorship needs among younger adults.

Editorial currency note (October 13, 2026): National annual counts are projections, and observed surveillance data lag the publication year. Cost estimates use different price years and methodologies; screening recommendations, Medicare coverage rules and ongoing clinical-trial evidence can change. In particular, some older screening summaries predate the September 2026 NHS-Galleri randomized results. This article synthesizes population evidence and practical resources; individual screening, diagnostic and treatment decisions should be discussed with a qualified healthcare professional.